13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001131399
Total reported value
$602.2M
$602.2M
13 檔
80.6%
As reported in its official Q1 2026 Form 13F filing, GSK plc's tracked investment portfolio stood at $602.2M with 13 total positions.
In Q1 2026, GSK plc adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 2 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including CRSP, WVE, BNTX) accounted for 80.6% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 25.57% | +3.60% | — | |
| 2 | WVE | Wave Life Sciences Ltd. | Stock-Other | 22.08% | -4.48% | — | |
| 3 | BNTX | Biontech Se-adr | Stock-Other | 13.20% | +0.55% | — | |
| 4 | VIR | Vir Biotechnology Inc | Stock-Other | 12.79% | +1.68% | — | |
| 5 | IDYA | Ideaya Biosciences Inc | Stock-Other | 7.41% | +0.84% | — | |
| 6 | LYEL | Lyell Immunopharma Inc | Stock-Other | 5.06% | -1.53% | — | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.74% | +1.08% | — | |
| 8 | SPRO | Spero Therapeutics Inc | Stock-Other | 3.59% | -0.22% | — | |
| 9 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.29% | -1.20% | — | |
| 10 | CVRX | Cvrx Inc | Stock-Other | 1.59% | -0.73% | — | |
| 11 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.18% | -0.10% | — | |
| 12 | NKTX | Nkarta Inc | Stock-Other | 1.11% | +0.37% | — | |
| 13 | RGNX | Regenxbio Inc | Stock-Other | 0.38% | +0.16% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VIR | Vir Biotechnology Inc | +6.3% | — | Unchanged |
| 2 | CRSP | CRISPR Therapeutics AG | +4.4% | — | Unchanged |
| 3 | BNTX | Biontech Se-adr | +2.6% | — | Unchanged |
| 4 | IDYA | Ideaya Biosciences Inc | +1.6% | — | Unchanged |
| 5 | CYTK | Cytokinetics Inc | +1% | — | Unchanged |
| 6 | SPRO | Spero Therapeutics Inc | +0.9% | — | Unchanged |
| 7 | CVRX | Cvrx Inc | +0.7% | — | Unchanged |
| 8 | NKTX | Nkarta Inc | +0.4% | — | Unchanged |
| 9 | RGNX | Regenxbio Inc | -0.1% | — | Unchanged |
| 10 | BCYC | Bicycle Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 11 | FULC | Fulcrum Therapeutics Inc | -0.2% | — | Unchanged |
| 12 | LYEL | Lyell Immunopharma Inc | -0.8% | — | Unchanged |
| 13 | WVE | Wave Life Sciences Ltd. | -16.7% | — | Unchanged |
| 14 | SENS | Senseonics Holdings Inc | — | EXIT | Sold out |
| 15 | HBIOUSD | Harvard Bioscience Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, GSK plc reported a total U.S. public equity portfolio value of $602.2M across 13 disclosed positions in Q1 2026.
During Q1 2026, GSK plc's top holdings by market value included CRSP (25.6%)、WVE (22.1%)、BNTX (13.2%). The largest single position, CRSP, represented 25.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top Position Liquidated / Trimmed
SENS
前期市值: $59.9K
In Q1 2026, GSK plc made 2 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.